• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high small cell lung cancer: results from the Phase 3 TAHOE study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    33607312.pdf
    Size:
    405.2Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Blackhall, Fiona H
    Jao, K.
    Greillier, L.
    Cho, B. C.
    Penkov, K.
    Reguart, N.
    Majem, M.
    Nackaerts, K.
    Syrigos, K.
    Hansen, K.
    Schuette, W.
    Cetnar, J.
    Cappuzzo, F.
    Okamoto, I.
    Erman, M.
    Langer, S. W.
    Kato, T.
    Groen, H.
    Sun, Z.
    Luo, Y.
    Tanwani, P.
    Caffrey, L.
    Komarnitsky, P.
    Reinmuth, N.
    Show allShow less
    Affiliation
    University of Manchester and Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: Fiona.Blackhall@christie.nhs.uk. Hopital du Sacre Coeur Montreal, Montreal, Canada. Aix-Marseille University, APHM, INSERM, CNRS, CRCM, Marseille, France. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Private Medical Institution Euromedservice, St. Petersburg, Pushkin, Russian Federation. Hospital Clinic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona, Spain. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. KU Leuven, University Hospital Leuven, Leuven, Belgium. National & Kapodistrian University of Athens, Athens, Greece. Odense Universitets Hospital, Odense, Denmark. Krankenhaus Martha-Maria Halle-Doelau Halle, Germany. Oregon Health & Science University, Portland, Oregon, USA. Istituto Nazionale Tumori IRCCS Regina Elena, Roma, Italy. Kyushu University Hospital, Fukuoka, Japan. Hacettepe University, Cancer Institute, Ankara, Turkey. Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. Kanagawa Cancer Center, Yokohama, Japan. University of Groningen and University Medical Center Groningen, Groningen, Netherlands. AbbVie, Inc, North Chicago, Ilinois, USA. Asklepios Fachkliniken München-Gauting, Gauting, Germany.
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Introduction: Delta-like protein 3 (DLL3), an atypical Notch ligand, is expressed in small cell lung cancer (SCLC) tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine via a protease-cleavable linker. Efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated. Methods: TAHOE was an open-label, 2:1 randomized, phase 3 study comparing Rova-T with topotecan as second-line therapy in DLL3-high advanced or metastatic SCLC. Rova-T (0.3 mg/kg) was administered intravenously on Day 1 of a 42-day cycle for 2 cycles, with 2 additional cycles available to patients who met protocol-defined criteria for continued dosing. Topotecan (1.5 mg/m2) was administered intravenously on Days 1-5 of a 21-day cycle. The primary endpoint was overall survival (OS). Results: Patients randomized to Rova-T (n=296) and topotecan (n=148) were included in efficacy analyses. The median age was 64 years, and 77% had extensive disease at initial diagnosis. Median OS (95% CI) was 6.3 months (5.6-7.3) in the Rova-T arm and 8.6 months (7.7, 10.1) in the topotecan arm (hazard ratio, 1.46 [95% CI: 1.17-1.82]). An independent data monitoring committee recommended that enrollment be discontinued due to shorter OS observed with Rova-T compared with topotecan. Safety profiles for both drugs were consistent with previous reports. Conclusions: Compared with topotecan, which is the current standard second-line chemotherapy, Rova-T showed an inferior OS and higher rates of serosal effusions, photosensitivity reaction, and peripheral edema in patients with SCLC. Significant unmet therapeutic need remains in this population.
    Citation
    Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. J Thorac Oncol. 2021.
    Journal
    Journal of Thorac Oncology
    URI
    http://hdl.handle.net/10541/623834
    DOI
    10.1016/j.jtho.2021.02.009
    PubMed ID
    33607312
    Additional Links
    https://dx.doi.org/10.1016/j.jtho.2021.02.009
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.jtho.2021.02.009
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
    • Authors: Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J
    • Issue date: 2021 Sep
    • Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    • Authors: Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP
    • Issue date: 2019 Dec 1
    • Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
    • Authors: Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I
    • Issue date: 2019 Sep
    • A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
    • Authors: Hann CL, Burns TF, Dowlati A, Morgensztern D, Ward PJ, Koch MM, Chen C, Ludwig C, Patel M, Nimeiri H, Komarnitsky P, Camidge DR
    • Issue date: 2021 Sep
    • Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
    • Authors: Calvo E, Spira A, Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburton L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B
    • Issue date: 2021
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.